Abstract: The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
May 3, 2022
Assignees:
INSERM (Institut National de la Santéet de la Recherche Médicale), UniversitéPaul Sabatier Toulouse III, Institut Claudius Regaud
Inventors:
Aurelien Olichon, Laura Keller, Gilles Favre, Nicolas Bery, Patrick Chinestra
Abstract: The present embodiments provide for an S. aureus (SA) Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces an immune response, where at least one S. aureus (SA) peptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. In some embodiments, the immunogenic polysaccharide can be an antigenic capsular polysaccharide of a Type 5 or Type 8 from S. aureus, or alternatively, a different immunogenic capsular or noncapsular polysaccharide, and where the protein or peptide SA antigens are indirectly linked via an affinity binding pair. The present SA-MAPS immunogenic compositions can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one or multiple SA antigens at the same time.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
April 19, 2022
Assignee:
The Children's Medical Center Corporation
Abstract: Fusion molecules composed of a type I interferon protein or portion thereof and a type III interferon protein or portion thereof, pharmaceutical compositions containing the fusion molecules, and methods for their use in inhibiting infection, inhibiting or treating cancer, inducing signaling of transcription of IFN-stimulated genes through an IFN-?R2 chain in a subject suffering from an infection which degrades or downregulates an IFN-?R1 chain, and treating various diseases or conditions are provided.
Type:
Grant
Filed:
May 1, 2018
Date of Patent:
April 5, 2022
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Inventors:
Sergei V. Kotenko, Joan Durbin, Viralkumar Rameshkumar Davra
Abstract: The present invention relates to a novel protein formulation. In particular, the invention relates to a liquid pharmaceutical composition of tocilizumab, a method of manufacturing the composition, a kit including the composition, a package including the composition and to methods of treatment using the composition and/or package.
Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.
Abstract: The disclosure provides buffered formulations of adalimumab. The formulations comprise a buffer comprising an acetate salt, sorbitol, histidine and/or a histidine salt and optionally arginie and/or an arginine salt, and polysorbate 80. The formulations have an acidic pH, and enhance the thermal, conformational and colloidal stability of antibodies, including the adalimumab antibody.
Type:
Grant
Filed:
February 1, 2017
Date of Patent:
March 29, 2022
Assignee:
Outlook Therapeutics, Inc.
Inventors:
Hiten Gutka, Maria Taddei, Jessica Cheung
Abstract: Disclosed herein are methods that employ the use of one or more biomarkers for the treatment of SARS-CoV-2 infected individuals (COVID-19 patients). The methods may employ detection and measurement of one or more cytokines, the measurement of which may be used to treat COVID-19 patients with one or more immunomodulatory therapies.
Abstract: Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.
Type:
Grant
Filed:
December 21, 2017
Date of Patent:
March 8, 2022
Assignee:
Cephalon, Inc.
Inventors:
David Jose Simon Laine, Matthew Pollard, Anthony Gerard Doyle, Lynn Dorothy Poulton, Adam William Clarke
Abstract: Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.
Type:
Grant
Filed:
August 7, 2017
Date of Patent:
February 15, 2022
Assignee:
Y-BIOLOGICS INC.
Inventors:
Jae Eun Park, Soo Young Kim, Hyun Mi Lee, Si Hyung Lee, Hyun Kyung Lee, Hye-Nan Kim, Jin Chui Youn, Bum-chan Park, Jung Chae Lim, Young-Gyu Cho, Young Woo Park
Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
Type:
Grant
Filed:
February 6, 2018
Date of Patent:
February 15, 2022
Assignees:
VIB VZW, Centre National de la Recherche Scientifique, Univeriteit Gent, Universite de Montpellier
Inventors:
Jan Tavernier, Jose Van Der Heyden, Genevieve Garcin, Gilles Uze, Yann Bordat
Abstract: The present disclosure describes a method of treating immunological disorders, for example alloimmune and autoimmune diseases, using a pharmaceutical composition comprising at least one mesenchymal stromal cell-derived protein Further disclosed herein is the use of the pharmaceutical composition for immunomodulation.
Type:
Grant
Filed:
February 22, 2019
Date of Patent:
February 15, 2022
Assignee:
Singapore Health Services Pte Ltd
Inventors:
Xiubo Fan, William Ying Khee Hwang, Hsiu Ling Low, Julian Thumboo, Chin Teck Ng
Abstract: Disclosed are fusion polypeptides comprising fragments from a first and a second isoform of an interferon lambda family, nucleic acids encoding the fusion polypeptides, and vectors and host cells containing the same, and methods of making and using such compositions in treatment of interferon lambda-related diseases, disorders, and conditions.
Type:
Grant
Filed:
January 18, 2019
Date of Patent:
February 8, 2022
Assignee:
Prosit Sole Biotechnology (Beijing) Co, Ltd
Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
Type:
Grant
Filed:
March 26, 2020
Date of Patent:
February 1, 2022
Assignee:
Swedish Orphan Biovitrum AG
Inventors:
Cristina De Min, Walter Ferlin, Fabrizio De Benedetti
Abstract: The invention encompasses methods of treatment of interferon gamma (IFN-?)-mediated diseases using IFN-? inhibitors, such as anti-huIFN-? antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-? inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-? antibody.
Type:
Grant
Filed:
August 31, 2017
Date of Patent:
January 25, 2022
Assignee:
AMGEN INC.
Inventors:
Andrew A. Welcher, Michael J. Boedigheimer, James B. Chung
Abstract: Described herein are methods and genetically engineered fungal cells useful for producing target molecules containing mammalian-like complex N-glycans or containing intermediates in a mammalian glycosylation pathway.
Type:
Grant
Filed:
April 11, 2019
Date of Patent:
January 18, 2022
Assignee:
Oxyrane UK Limited
Inventors:
Steven Christian Jozef Geysens, Wouter Vervecken
Abstract: The present invention relates to a stabilized pharmaceutical preparation of R27T, the preparation comprising a human interferon beta variant (R27T), an acetate buffer, arginine, trehalose, Poloxamer 188, and methionine. The stabilized R27T pharmaceutical preparation according to the present invention is obtained by the development of a preparation having a novel composition through the substitution of mannitol with trehalose in the composition of a preparation containing mannitol, which was previously studied by the present inventors.
Abstract: GM-CSF variants, polynucleotides encoding them, and methods of making and using the foregoing are useful in treatment of immune-related disorders, such as inflammatory bowel disease (IBD).
Type:
Grant
Filed:
January 17, 2020
Date of Patent:
December 28, 2021
Assignee:
Janssen Biotech, Inc.
Inventors:
Thomas Rutkoski, Alexey Teplyakov, Nicole Wunderler